Related Experiment Videos
Review: practical issues in intravitreal drug delivery
1Department of Ophthalmology, Columbia University, New York, New York 10032, USA. dmm35@columbia.edu
Summary
Visual loss limits drug effectiveness in the retina. Condensed drug depots anchored outside the visual pathway, like a scleral reservoir, offer extended drug delivery and flexibility for retinal treatments.
Area of Science:
- Ophthalmology
- Pharmacokinetics
- Drug Delivery Systems
Background:
- Drug delivery to the retina faces challenges including pharmacokinetics, visual interference, and safety.
- Current methods like solutions and microdispersions have limitations in duration and efficacy.
Purpose of the Study:
- To evaluate drug delivery strategies for the retina.
- To identify optimal methods for prolonged drug release and minimize visual impairment.
Main Methods:
- Pharmacokinetic analysis of drug delivery from solution and prolonged-release forms.
- Assessment of visual interference, toxicity, and safety profiles.
- Conceptualization of novel drug delivery systems.
Main Results:
- Visual loss is the primary limiting factor for microdispersion drug delivery to the retina.
- Condensed drug depots can extend therapeutic lifetime but require surgical implantation.
- Diffusion from the vitreous limits the duration of microparticle-based delivery.
Conclusions:
- Anchoring drug depots outside the visual pathway, such as a scleral reservoir with controlled vitreous entry, offers a flexible and potentially longer-lasting retinal drug delivery solution.
- Minimizing visual pathway interference is crucial for sustained retinal drug therapy.
- Advanced drug delivery systems are needed to overcome current limitations in treating retinal diseases.